Core Viewpoint - The recent announcement by China Europe Fund regarding the purchase limit on the China Europe Medical Innovation fund is aimed at ensuring stable fund operations and protecting the interests of fund shareholders, reflecting a broader trend of purchase limits across various high-performing funds in the market [1][4][8]. Fund Management and Performance - The China Europe Medical Innovation fund, managed by fund manager Ge Lan, will impose a purchase limit of 100,000 yuan per day per account starting from August 11, 2025 [1][4]. - As of August 8, 2023, the net value increase of the China Europe Medical Innovation A fund reached 62.28% year-to-date, with an 80.12% increase over the past year, ranking it among the top three in its category [6]. - Another fund managed by Ge Lan, the China Europe Medical Health A fund, also reported a year-to-date net value increase of 21.81% as of August 8, 2023 [6]. Market Trends and Fund Limitations - Approximately 50 actively managed equity funds have announced purchase limits in the second half of the year, including high-performing products like the China Europe Medical Innovation fund and others [3][8]. - The trend of limiting purchases is attributed to the need to maintain fund stability and protect existing shareholders' interests, as excessive inflows could dilute returns for current investors [11]. Investment Outlook - Ge Lan expressed optimism about the innovative drug sector, highlighting advancements in dual antibodies and ADC technologies, as well as the increasing collaboration between domestic companies and multinational pharmaceutical firms [7]. - The domestic innovative drug sector is expected to gain global recognition, with multiple products anticipated to have overseas licensing opportunities, supported by favorable domestic policies [7].

Core Viewpoint - Recent announcements from multiple high-performing funds under China Europe Fund indicate a trend of limiting large purchases to ensure stable fund operations and protect the interests of existing fund holders [1][3][15]. Fund Purchase Limitations - On August 9, China Europe Fund announced that starting from August 11, the China Europe Medical Innovation Fund would limit single-day purchases to 100,000 yuan per account [3][5]. - This is not the first instance; a similar limit was imposed on another medical fund managed by the same manager, Guo Lan, since January 2021 [1][2]. Fund Performance and Holdings - As of mid-2023, the China Europe Medical Innovation Fund had a total net asset value exceeding 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the portfolio, respectively [6][7]. - The top ten holdings of the fund include notable companies such as Sanofi Pharmaceutical and WuXi AppTec, with significant year-to-date price increases, including a nearly 400% rise for the largest holding, Sanofi Pharmaceutical [6][8]. Market Trends and Reactions - The recent surge in the innovative drug sector has led to substantial gains for the fund's holdings, with an average increase of over 100% for the top ten stocks this year [7][8]. - The fund's unit net value has also risen significantly, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [9]. Broader Industry Context - The trend of limiting fund purchases is not isolated; approximately 50 actively managed equity funds have announced similar restrictions since July, reflecting a broader industry response to rapid inflows and the need to maintain investment strategy effectiveness [14][15]. - Industry experts suggest that these measures are aimed at controlling fund size to enhance investment efficiency and protect existing investors from potential losses due to market volatility [15][16].